GLP-1 receptor agonist and use thereof

Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonis...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Jung Ho, JE, In-gyu, JEON, Woo Jin, IM, A-rang, SHIN, Jae Eui, CHANG, Min Whan, KIM, Kyeojin, KIM, Jeong-geun, JEONG, Jin Ah, KWON, Sung Wook, LEE, Jin Hee, JANG, Eun Hye, LEE, Myong Jae, SOHN, Te-ik, OH, Changmok, HONG, Changhee, HONG, Da Hae, KIM, Gunhee, PARK, Jung-eun, CHOI, Ji Hye, HEO, Jaeho, YOO, Yeongran, AN, Kyung Mi, JUN, Yearin, YOON, Hong Chul
Format Patent
LanguageEnglish
Published 23.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
Bibliography:Application Number: AU20200384121